IRHYTHM HLDGS (IRTC) shares ended the last trading session 5% higher at $163.24. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 7.4% loss over the past four weeks.IRHYTHM HLDGS  recorded a strong price rise on investors’ optimism surrounding the company’s announcement of preliminary fourth quarter operational highlights. The company expects full year 2025 revenue to exceed high end of previously stated guidance ra ...

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Hinge Health Inc. (HNGE) , which belongs to the Zacks Medical Info Systems industry, could be a great candidate to consider.When looking at the last two reports, this company has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 343.06%, on average, in the last two quarters.For the most recent quarter, Hinge ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Assertio (ASRT) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Assertio is a member of our Medical group, which includes 932 different companies and cur ...

Company Performance - Doximity (DOCS) closed at $41.36, down 5.7% from the previous trading session, underperforming the S&P 500's loss of 0.19% [1] - Over the past month, Doximity shares have decreased by 1.77%, while the Medical sector gained 0.48% and the S&P 500 increased by 2.26% [1] Upcoming Earnings - Doximity is expected to report an EPS of $0.44, a decrease of 2.22% compared to the same quarter last year [2] - Revenue is projected at $181.03 million, reflecting a 7.37% increase from the equivalent quarter last year [2] Annual Forecast - Zacks Consensus Estimates forecast earnings of $1.56 per share and revenue of $645.29 million for the year, indicating increases of 9.86% and 13.13% respectively compared to the previous year [3] - Changes in analyst estimates for Doximity are important as they reflect short-term business trends [3] Analyst Ratings - The Zacks Rank system rates Doximity as 2 (Buy), with a history of outperforming the market, particularly 1 stocks returning an average annual gain of 25% since 1988 [5] - The Zacks Consensus EPS estimate has increased by 0.78% in the past month [5] Valuation Metrics - Doximity has a Forward P/E ratio of 28.04, which is a discount compared to the industry average Forward P/E of 29.42 [6] - The PEG ratio for Doximity is currently 1.48, while the Medical Info Systems industry has an average PEG ratio of 2.33 [6] Industry Context - The Medical Info Systems industry is ranked 160 in the Zacks Industry Rank, placing it in the bottom 35% of over 250 industries [7] - Top-rated industries (top 50%) tend to outperform the bottom half by a factor of 2 to 1 [7]

Core Insights - The Zacks Equity Research team has highlighted several stocks, including Meta Platforms, Bank of America, Procter & Gamble, Espey Mfg. & Electronics, and NeurAxis, in their recent analysis [1][2] Meta Platforms, Inc. (META) - Meta's shares have outperformed the Zacks Internet - Software industry over the past year, with a gain of +3.6% compared to the industry's +1.1% [4] - The company is experiencing steady user growth, particularly in the Asia Pacific region, driven by increased engagement across its platforms like Instagram, WhatsApp, Messenger, and Facebook [4] - Meta is leveraging AI to enhance its platform offerings, reaching over 3.54 billion users daily, which is expected to drive top-line growth [5] - The company plans to invest significantly in developing advanced AI models, although monetization of these services may take time [6] Bank of America Corp. (BAC) - Bank of America's shares have increased by +16.2% over the past six months, slightly underperforming the Zacks Financial - Investment Bank industry's gain of +17.3% [7] - The company's net interest income (NII) is projected to grow at a CAGR of 5.7% by 2027, supported by decent loan growth despite rate cuts [7] - Total revenues are expected to grow by 6.9% in 2025, although trading revenue growth may normalize after a robust performance since 2022 [8] - Elevated expenses due to ongoing investments and weak asset quality may hinder bottom-line growth, with expenses expected to rise by 4.3% in 2025 [9] The Procter & Gamble Co. (PG) - Procter & Gamble's shares have declined by -10.4% over the past six months, slightly better than the Zacks Consumer Products - Staples industry's decline of -11% [10] - The company anticipates all-in sales growth of 1–5% and organic sales gains of flat to up 4% in fiscal 2026, supported by cost savings [11] - Robust cash flow is expected to fund $15 billion in shareholder returns in fiscal 2026, including dividends and share buybacks [11] - However, elevated commodity costs and macroeconomic challenges continue to pressure margins and earnings visibility [12] Espey Mfg. & Electronics Corp. (ESP) - Espey Mfg. & Electronics has outperformed the Zacks Electronics - Military industry over the past six months, with a gain of +3.5% compared to the industry's decline of -32.4% [13] - The company has a backlog of $141.1 million, with 72% scheduled through 2028+, ensuring revenue visibility despite a 12.9% sales decline in Q1 FY26 [13] - Gross margin has expanded to 35.4%, indicating strong cost control and product mix advantages [14] NeurAxis, Inc. (NRXS) - NeurAxis has outperformed the Zacks Medical Info Systems industry over the past six months, with a gain of +65.2% compared to the industry's decline of -16.2% [16] - The company targets a large market for gut/brain disorders with its FDA-cleared IB-Stim neuromodulation system, recently expanding its addressable market to $8 billion [16] - Revenue has been growing at double-digit rates, but the company continues to face losses due to high spending and margin pressure [17]

Core Insights - The Zacks Equity Research team has highlighted several stocks, including AbbVie Inc., The Coca-Cola Co., Chevron Corp., ImmuCell Corp., and Precipio, Inc., in their Analyst Blog [1][2]. AbbVie Inc. (ABBV) - AbbVie has outperformed the Zacks Large Cap Pharmaceuticals industry over the past year, with a share price increase of +31.6% compared to the industry’s +19.5% [4]. - The company has successfully managed the loss of exclusivity for Humira by launching new immunology drugs, Skyrizi and Rinvoq, which are performing well and expected to support revenue growth [4][5]. - AbbVie is returning to robust revenue growth in 2025, following the U.S. Humira loss of exclusivity, and has been actively acquiring companies to enhance its early-stage pipeline [5]. The Coca-Cola Co. (KO) - Coca-Cola's shares have outperformed the Zacks Beverages - Soft Drinks industry over the past year, with a gain of +14.5% compared to +10.5% for the industry [6]. - The company's performance is attributed to solid organic revenue growth, effective pricing strategies, and gains in global market share within the non-alcoholic ready-to-drink category [6][7]. - Ongoing innovation and digital transformation efforts are enhancing Coca-Cola's competitive edge, although the company faces challenges such as soft volumes in key regions and currency headwinds [7][8]. Chevron Corp. (CVX) - Chevron's shares have increased by +9.5% over the past year, while the Zacks Oil and Gas - Integrated - International industry has gained +16% [9]. - The acquisition of Hess has significantly improved Chevron's growth outlook by adding high-quality assets in regions like Guyana and the Gulf of Mexico [9]. - The Permian Basin remains a key asset for Chevron, driving consistent growth, although challenges such as lower crude realizations and regulatory issues in California temper optimism [10]. ImmuCell Corp. (ICCC) - ImmuCell has outperformed the Zacks Medical - Products industry with a share price increase of +26.3% compared to +1% for the industry [11]. - The company’s First Defense franchise leads the market in calf scours prevention, with Tri-Shield accounting for 70% of volume and a 48% market share [11][12]. - ImmuCell has resolved operational bottlenecks, restoring capacity to $30 million in annual sales, with TTM revenues of $27.8 million, reflecting a 16% year-over-year increase [12][13]. Precipio, Inc. (PRPO) - Precipio's shares have surged by +361.2% over the past year, significantly outperforming the Zacks Medical Info Systems industry, which saw a decline of -1.3% [14]. - The company is moving towards self-funded growth, driven by its Pathology Services division, which is experiencing steady organic growth and rising margins [14][15]. - Precipio has improved profitability and cash flow, although it faces risks related to liquidity and regulatory uncertainties [15][16].

Company Performance - Doximity (DOCS) closed at $43.53, down 3.22% from the previous day's closing price, underperforming the S&P 500 which gained 0.46% [1] - The stock has decreased by 9.95% over the past month, while the Medical sector gained 1.59% and the S&P 500 increased by 4.22% [1] Upcoming Financial Results - Doximity is expected to report an EPS of $0.44, a decrease of 2.22% compared to the same quarter last year [2] - Revenue is projected to be $181.03 million, reflecting a 7.37% increase from the equivalent quarter last year [2] Fiscal Year Projections - For the entire fiscal year, earnings are projected at $1.56 per share, representing a 9.86% increase from the prior year [3] - Revenue for the fiscal year is estimated at $645.29 million, indicating a 13.13% increase from the previous year [3] Analyst Estimates and Revisions - Recent modifications to analyst estimates for Doximity indicate short-term business trends, with upward revisions suggesting positive sentiment towards the company's operations [4] - The Zacks Rank system, which incorporates these estimate changes, currently ranks Doximity at 3 (Hold) [6] Valuation Metrics - Doximity has a Forward P/E ratio of 28.75, which is a discount compared to the industry average Forward P/E of 46.25 [6] - The company has a PEG ratio of 1.52, significantly lower than the Medical Info Systems industry's average PEG ratio of 3.49 [7] Industry Context - The Medical Info Systems industry, part of the Medical sector, holds a Zacks Industry Rank of 102, placing it in the top 42% of over 250 industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [8]

Investors in Evolent Health, Inc. (EVH) need to pay close attention to the stock based on moves in the options market lately. That is because the Jan 16, 2026 $25 Call had some of the highest implied volatility of all equity options today.What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also ...

Veeva Systems Inc. (NYSE:VEEV) faces a downgrade by KeyBanc to a Sector Weight rating amidst a 22.8% decline over the past month.The stock's underperformance is highlighted against the Zacks S&P 500 composite's slight increase of 0.9%.Despite market downturns, Veeva's market capitalization of approximately $37.72 billion and active trading volume suggest continued investor interest.Veeva Systems Inc. (NYSE:VEEV) is a prominent player in the cloud-based software industry, primarily serving the life sciences ...

Core Viewpoint - Clover Health Investments reported a mixed earnings performance for Q3 2025, with revenues increasing significantly but missing earnings expectations, leading to a decline in stock price [2][3][10]. Financial Performance - Clover Health reported adjusted quarterly earnings per share (EPS) of break-even, missing the Zacks Consensus Estimate of 2 cents, compared to an adjusted loss of 2 cents in the same period last year [2]. - Revenues for the quarter reached $496.7 million, reflecting a year-over-year increase of 50.1% and surpassing the Zacks Consensus Estimate by 4.5% [3]. - Insurance revenues totaled $479.1 million, up 48.5% year over year, driven by a 35% increase in Medicare Advantage membership and strong member retention [4]. Expense and Loss Analysis - The Insurance Benefit Expense Ratio (BER) was reported at 92.4%, up from 85.4% in the previous year, attributed to new-member growth and increased medical utilization [5]. - Net medical claims rose 70.5% year over year to $428.9 million, while total operating expenses increased by 53.3% to $521 million [7]. Financial Position - At the end of Q3 2025, Clover Health had cash and cash equivalents of $190.1 million, slightly up from $188.6 million at the end of the previous quarter [8]. - Net cash provided by operating activities from continuing operations was $1.2 million, a significant decrease from $129.5 million a year ago [8]. Guidance and Outlook - The company raised its sales outlook for 2025, estimating Insurance revenues between $1.85 billion and $1.88 billion, indicating a 39% year-over-year growth at the midpoint [10]. - Adjusted Net Income guidance was lowered to a range of $15 million to $30 million, down from a previous estimate of $50 million to $70 million [10]. - The Insurance BER projection was raised to 90-91%, and average Medicare Advantage membership is expected to grow by 33% year over year [11]. Market Position and Comparisons - Clover Health has a Zacks Rank of 3 (Hold), indicating an expectation of in-line returns in the coming months [14]. - In comparison, Omnicell, a peer in the Medical Info Systems industry, has seen a stock gain of 13.3% over the past month, highlighting a contrasting performance within the sector [15].